Didronel (Etidronate)

Photograph of Didronel (Etidronate) under the microscope.

Didronel is used primarily to treat Paget's disease of bone, although it is sometimes used for bone therapy following hip replacement or surgery. The drug inhibits the formation, growth and dissolution of hydroxyapatite crystals and their amorphous precursors by chemisorption to calcium phosphate surfaces. The drug is not metabolized and only half of the drug is excreted through urine, the other half being distributed throughout bone.Side effects include bone pain or tenderness, and more rarely, hives and skin rash.

© 1995-2022 by Michael W. Davidson and The Florida State University. All Rights Reserved. No images, graphics, software, scripts, or applets may be reproduced or used in any manner without permission from the copyright holders. Use of this website means you agree to all of the Legal Terms and Conditions set forth by the owners.
This website is maintained by our
Graphics & Web Programming Team
in collaboration with Optical Microscopy at the
National High Magnetic Field Laboratory.
Last modification: Monday, Jul 02, 2018 at 04:22 PM
Access Count Since April 15, 1997: 43714